July 01, 2024
Caribou Biosciences Inc. has agreed to pay $3.9 million to settle a proposed class action alleging it misled investors about the durability of its most advanced cancer-fighting therapy before and after the gene-editing biotechnology company went public, investors told a California federal judge on Friday.
November 16, 2023
Gene-editing biotechnology firm Caribou Biosciences Inc. wants a proposed shareholder class action accusing it of misleading investors about the durability of its top cancer-fighting therapy to be dismissed, arguing the investor cannot show the statements were known to be false when they were made.
April 12, 2023
Shareholders hit Caribou Biosciences Inc. with a class action Tuesday alleging the gene-editing biotechnology firm misled investors about the durability of its top cancer-fighting therapy leading up to and after its July 2021 initial public offering.